Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  McCrudden, Cian M ^a   O'Rourke, Martin G ^a   Cherry, Kim E ^a   Yuen, Hiu Fung ^a   O'Rourke, Declan ^b   Babur, Muhammad ^c   Telfer, Brian A ^c   Thomas, Huw D ^d   Keane, Patrick ^b   Nambirajan, Thiagarajan ^b   Hagan, Chris ^b   O'Sullivan, Joe M ^a,b   Shaw, Chris ^a   Williams, Kaye J ^c   Curtin, Nicola J ^d   Hirst, David G ^a   Robson, Tracy ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; MYOSIN LIGHT CHAIN KINASE; N(G) METHYLARGININE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PURINERGIC P2 RECEPTOR; RUCAPARIB; SURAMIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; PARP1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; MALE; MOUSE; MUSCLE RELAXATION; NONHUMAN; PHARMACOPHORE; PROTEIN FOLDING; RAT; RECEPTOR BLOCKING; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; VASCULAR TISSUE; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; DEFICIENCY; DRUG EFFECTS; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PHYSIOLOGY; VASCULARIZATION; WISTAR RAT;

MUS; RATTUS;

ANIMALS; AORTA; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE; MYOSIN-LIGHT-CHAIN KINASE; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2; VASODILATION;

EID: 84923310357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118187     Document Type: Article

References (38)

1. Quenet D, El Ramy R, Schreiber V, Dantzer F. The role of poly (ADP-ribosyl) ation in epigenetic events. Int J BiochemCell Biol 2009;41:60-65. doi: 10.1016/j.biocel.2008.07.023 PMID: 18775502
2. Schreiber V, Dantzer F, Ame JC, De Murcia G. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-528. PMID: 16829982
3. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013;34:1217-1256. doi: 10.1016/j.mam.2013.01.006 PMID: 23370117
4. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, et al. Tricyclic benzimidazoles as potent poly (ADP-ribose) polymerase-1 inhibitors. J Med Chem 2003;46:210-213. PMID: 12519059
5. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67. PMID: 14709739
6. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly (ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-6015. PMID: 14522929
7. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol CancerTher 2007;6:945-956. PMID: 17363489
8. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006;24:8013-0.
9. Horsman MR, Chaplin DJ, Brown JM. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res 1989;118:139-150. PMID: 2523079
10. Ruddock MW, Hirst DG. Nicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: implications for anticancer efficacy. Oncol Res 2004;14:483-489. PMID: 15559762
11. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly (ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 2009;15:6106-6112. doi: 10.1158/1078-0432. CCR-09-0398 PMID: 19789326
12. De Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7307. PMID: 9207086
13. Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer 2014;110:1977-1984. doi: 10.1038/bjc.2014.91 PMID: 24556618
14. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606. PMID: 17308057
15. Ruddock MW, Burns DM, McKeown SR, Murphy L, Walsh IK, Keane PF, et al. Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide. Radiother Oncol 2000;54:179-184. PMID: 10699482
16. Wallace A, Knight GE, Cowen T, Burnstock G. Changes in purinergic signalling in developing and ageing rat tail artery: importance for temperature control. Neuropharmacology 2006;50:191-208. PMID: 16226282
17. Dalziel HH, Westfall DP. Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization. Pharmacol Rev 1994;46:449-466. PMID: 7899473
18. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 1998;336(Pt 3):513-523.
19. Mutafova-Yambolieva VN, Hwang SJ, Hao X, Chen H, Zhu MX, Wood JD, et al. Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci U S A 2007;104:16359-16364. PMID: 17913880
20. Pacher P, Vaslin A, Benko R, Mabley JG, Liaudet L, Hasko G, et al. Anew, potent poly (ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther 2004;311:485-491. PMID: 15213249
21. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, et al. Identification of potent nontoxic poly (ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9:2711-2718. PMID: 12855651
22. Cleaver JE, Morgan WF. 3-Aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, is a stimulator, not an inhibitor, of DNA repair. Exp Cell Res 1987;172:258-264. PMID: 3115799
23. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-288. doi: 10.1038/nbt.2121 PMID: 22343925
24. Gong MC, Cohen P, Kitazawa T, Ikebe M, Masuo M, Somlyo AP, et al. Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem 1992;267:14662-14668. PMID: 1321813
25. Deng M, Ding W, Min X, Xia Y. MLCK-independent phosphorylation of MLC20and its regulation by MAP kinase pathway in human bladder smooth muscle cells. Cytoskeleton (Hoboken) 2011;68:139-149. doi: 10.1002/cm.20471 PMID: 20722044
26. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol (1985) 2001;91:1421-1430. PMID: 11509544
27. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circ Res 2001;89:684-691. PMID: 11597991
28. English FA, McCarthy FP, Andersson IJ, Stanley JL, Davidge ST, Baker PN, et al. Administration of the PARP inhibitor Pj34 ameliorates the impaired vascular function associated with eNOS (-/-) mice. ReprodSci 2012;19:806-813. doi: 10.1177/1933719111433885 PMID: 22421449
29. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, et al. Enhanced killing of cancer cells by poly (ADP-ribose) polymerase inhibitors andtopoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 2012;287:4198-4210. doi: 10.1074/jbc. M111.296475 PMID: 22158865
30. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012;72:5588-5599. doi: 10.1158/0008-5472. CAN-12-2753 PMID: 23118055
31. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Mol Cancer Ther 2014.
32. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ depletion is necessary and sufficient for poly (ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010;30:2967-2978. doi: 10.1523/JNEUROSCI.5552-09.2010 PMID: 20181594
33. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-7923. doi: 10.1158/1078-0432. CCR-08-1223 PMID: 19047122
34. Shapiro G, Kristeleit R, Middleton M, Burris H, Molife LR, Evans J, et al. Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors. Molecular Cancer Therapeutics 2013;12:A218-A218.
35. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, et al. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol CancerTher 2011;10:2320-2329. doi: 10. 1158/1535-7163. MCT-11-0356 PMID: 21926192
36. Pal SK, Mortimer J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009;63:269-274. doi: 10.1016/j.maturitas.2009.06.010 PMID: 19632796
37. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012;18:1655-1662. doi: 10.1158/1078-0432. CCR-11-2890 PMID: 22291137
38. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011;10:1949-1958. doi: 10.1158/1535-7163. MCT-11-0278 PMID: 21825006